These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 17940486)

  • 1. Low molecular weight heparin and bleeding in patients with chronic renal failure.
    Crowther M; Lim W
    Curr Opin Pulm Med; 2007 Sep; 13(5):409-13. PubMed ID: 17940486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
    George-Phillips KL; Bungard TJ
    Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile of different low-molecular weight heparins used at therapeutic dose.
    Gouin-Thibault I; Pautas E; Siguret V
    Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin in patients with chronic renal insufficiency.
    Lim W
    Intern Emerg Med; 2008 Dec; 3(4):319-23. PubMed ID: 18563531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings.
    Hull RD
    Thromb Haemost; 2008 Mar; 99(3):502-10. PubMed ID: 18327398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LMWH and renal failure: bleeding. Creatinine clearance should be checked before choosing heparin products.
    Prescrire Int; 2007 Dec; 16(92):251. PubMed ID: 18092423
    [No Abstract]   [Full Text] [Related]  

  • 11. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparins in patients with renal insufficiency.
    Symes J
    CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of thrombosis in pregnancy: role of low-molecular-weight heparin.
    Kher A; Bauersachs R; Nielsen JD
    Thromb Haemost; 2007 Apr; 97(4):505-13. PubMed ID: 17393011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suboptimal doses of low molecular weight heparin and acute venous thromboembolism. Data from the RIETE registry.
    Bruscas MJ; Nieto JA; Perez-Pinar M; López-Jiménez L; Fernández-Capitán C; López-Chuliá F; Orue-Lecue MT;
    Ann Hematol; 2007 Jul; 86(7):519-26. PubMed ID: 17437112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
    Clark NP
    Thromb Res; 2008; 123 Suppl 1():S58-61. PubMed ID: 18809206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
    Andrassy K
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin.
    Busby LT; Weyman A; Rodgers GM
    Am J Hematol; 2001 May; 67(1):54-6. PubMed ID: 11279659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants.
    DeLoughery TG
    Crit Care Clin; 2005 Jul; 21(3):497-512. PubMed ID: 15992670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thrombosis prophylaxis with heparins in intensive care patients].
    Greinacher A; Janssen D
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2005 Mar; 40(3):156-63. PubMed ID: 15770559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.